Bristol-Myers (BMY) is returning its share of global rights to blood thinner Plavix and blood...


Bristol-Myers (BMY) is returning its share of global rights to blood thinner Plavix and blood pressure treatment Avalide to Sanofi (SNY) following the loss of patent protection for the drugs, although the American firm will retain U.S. and Puerto Rico rights to Plavix. BMY will receive royalties until 2018 and then a $200M terminal payment, although it's paying $80M to Sanofi over supply disruption to Avalide in the U.S. in 2011. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs